Ultragenyx Pharmaceutical (RARE) EBITDA (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) EBITDA from Mar 31, 2013 to Mar 31, 2026. The TTM Ultragenyx Pharmaceutical (RARE) EBITDA is -$527M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Ultragenyx Pharmaceutical (RARE) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +10.37% |
| 3 Years TTM | -6.61% |
| 5 Years TTM | +11.69% |
| 10 Years TTM | +11.46% |
| All Time TTM | +25.23% |
Annual EBITDA change of Ultragenyx Pharmaceutical (RARE)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$161M | -67.80% |
| 2025 | -$500M | N/A |
| 2024 | -$500M | -7.92% |
| 2023 | -$543M | -13.91% |
| 2022 | -$631M | +71.15% |
| 2021 | -$369M | +15.94% |
| 2020 | -$318M | -23.53% |
| 2019 | -$416M | +18.13% |
| 2018 | -$352M | +8.89% |
| 2017 | -$323M | +32.11% |
| 2016 | -$245M | +67.12% |
| 2015 | -$146M | +160.92% |
| 2014 | -$56M | +76.16% |
| 2013 | -$32M | +103.19% |
| 2012 | -$16M | N/A |
Comparison Ultragenyx Pharmaceutical (RARE) five years EBITDA CAGR with competitors
Ultragenyx Pharmaceutical (RARE) five years EBITDA CAGR is 11.69%.